High-throughput screening platforms and the quest for universal geroprotectors across evolutionary models

The pursuit of pharmacological interventions to extend human longevity has long been hampered by the limitations of traditional, low-throughput laboratory testing. Historically, aging research has relied on manual, labor-intensive experiments conducted on single species, often resulting in findings that lack replicability across the biological spectrum. However, a recent milestone in the field—a comprehensive, multi-species screening campaign—has introduced a paradigm shift by utilizing integrated, automated platforms to evaluate over 400 compounds simultaneously across yeast, nematodes, fruit flies, killifish, and mice. This initiative, which parallels the total volume of existing literature for several of these models, marks a significant departure from isolated, siloed research, offering a more robust framework for identifying compounds that may function as truly conserved geroprotectors.

The Evolution of Longevity Screening

For decades, the aging research community has focused on short-lived model organisms such as Caenorhabditis elegans (nematodes) and Saccharomyces cerevisiae (budding yeast). These organisms are favored for their short lifespans and genetic malleability. The prevailing strategy has been to identify molecules that trigger beneficial stress-response pathways—such as autophagy, mitochondrial maintenance, and oxidative stress resistance—which are often activated by dietary restriction or environmental stressors like temperature fluctuation.

While these pathways have shown profound effects on longevity in short-lived invertebrates, their efficacy diminishes significantly in more complex, long-lived species. This discrepancy has created a "translation gap" that remains one of the primary obstacles in the field of geroscience. Scientists have long argued that without a way to rapidly screen thousands of compounds across a wide evolutionary distance, the search for drugs that might influence human aging would remain largely anecdotal and prone to failure when transitioning from the petri dish to the mammalian model.

Chronology of High-Throughput Innovation

The transition toward automated aging research began in earnest during the late 2010s, as advancements in machine learning and microfluidics began to converge.

• 2015–2018: Early efforts focused on individual species, with researchers developing rudimentary automated imaging systems to track nematode lifespan. These systems were limited by manual handling requirements and high rates of experimental error.
• 2019–2021: The integration of machine learning algorithms for "death detection" revolutionized the field. By utilizing computer vision to identify physiological markers of senescence and mortality, researchers successfully eliminated the need for human observation, which was previously a major bottleneck in longitudinal studies.
• 2022–2024: The development of standardized, miniaturized assay platforms allowed for the first truly integrated, multi-species studies. By creating "in-house" drug-pellet formulations for killifish and home-cage activity monitoring for mice, researchers were able to standardize oral delivery and health assessment across diverse biological architectures.
• 2025–2026: The current project represents the culmination of these developments, successfully executing a massive, coordinated screen that provides a unified dataset for five distinct biological models.

Methodology and Supporting Data

The platform described in this recent study represents a leap in experimental rigor. By moving away from manual "transfers"—a process where organisms are moved between plates, which can introduce stress and experimental bias—the team employed compact imaging platforms that keep subjects undisturbed. This "no-transfer" methodology is critical, as it ensures that the observed effects on lifespan are directly attributable to the chemical compound rather than procedural intervention.

The screening process utilized the following technical adaptations:

• Yeast (S. cerevisiae): A miniaturized flow cytometry assay was implemented to analyze chronological lifespan, allowing for rapid throughput while identifying common assay confounders that often lead to false positives.
• Nematodes and Flies: Machine learning models were trained to detect survival status based on movement and morphology, capturing not only lifespan data but also compound-specific, diet-dependent, and sex-dependent phenotypic changes.
• Killifish: Given the difficulty of administering medication to aquatic vertebrates, the team developed a standardized oral drug-pellet, ensuring consistent dosing across large cohorts.
• Mice: Researchers integrated long-term lifespan studies with non-invasive, home-cage activity monitoring, providing a high-fidelity look at how interventions affect physical vitality during the final stages of life.

Analyzing the Efficacy of Geroprotectors

One of the most sobering findings of this large-scale study is the rarity of truly conserved geroprotectors. When the researchers compared the results across all five models, they found that only a small subset of compounds produced consistent lifespan extension. This underscores a persistent challenge in the field: the "model-specificity" of longevity drugs. Many compounds that appear highly effective in worms or yeast fail to produce similar outcomes in mammals, suggesting that these molecules often act on highly specialized biological pathways that do not scale across evolutionary complexity.

However, the study also identified a core group of compounds that demonstrated significant positive effects across multiple species. This list includes:

• Baicalein: A flavonoid known for its antioxidant and anti-inflammatory properties.
• Doxycycline: A tetracycline antibiotic that has shown potential in modulating mitochondrial function.
• Forskolin: A compound often used in research to increase intracellular levels of cAMP.
• Metformin: A widely prescribed diabetes medication already under extensive investigation for its potential anti-aging properties.
• Resveratrol: A well-studied polyphenol associated with the activation of sirtuins.
• Rifampicin: A potent antibiotic that has previously shown efficacy in various aging models.

The identification of these specific compounds suggests that there is indeed a "tractable space" of pharmacological regulators that transcend species boundaries.

Implications for Future Aging Research

The implications of this research are twofold. First, the success of the platform confirms that high-throughput, automated screening is a viable—and perhaps necessary—direction for future aging research. By automating the data collection process, scientists can minimize the human element, reducing the likelihood of bias and increasing the statistical power of their findings. This creates a scalable pipeline that can be used to test vast libraries of novel compounds in the coming years.

Second, the study provides a critical reality check for the field. By demonstrating that most reported interventions are context-dependent, the research highlights the danger of over-relying on single-species data. The "first-of-its-kind" nature of this study serves as a benchmark, suggesting that future discoveries in the longevity space should be validated across multiple, evolutionary diverse models before they are touted as potential human therapeutics.

Experts in the field suggest that this methodology will likely be adopted by pharmaceutical companies and academic institutions alike. As the population continues to age globally, the demand for interventions that can compress morbidity and extend healthspan is reaching an all-time high. By refining the criteria for what constitutes a "conserved" geroprotector, this platform provides the scientific community with a more reliable map for navigating the complex biology of aging.

Furthermore, the integration of machine learning into survival scoring is expected to evolve, potentially incorporating multi-modal data such as metabolic profiles, epigenetic clocks, and proteomic signatures. As these technologies become more accessible, the speed at which we can identify potential longevity interventions will likely accelerate, moving from the current "screening" phase into a more targeted, mechanism-based approach to drug development.

While the "fountain of youth" remains an elusive goal, the systematic application of high-throughput platforms to the biology of aging represents a significant step toward a more rigorous, evidence-based approach to extending human vitality. By shifting the focus from isolated experiments to integrated, multi-species validation, researchers are establishing a foundation that is as durable as it is scientifically promising.